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Summary An immunoperoxidase technique has been utilised for the demonstration of follicle stimulating
hormone (FSH), luteinising hormone (LH) and prolactin (PRL) binding sites in normal human ovaries and in
a wide range of benign and malignant epithelial tumours of the ovary. The incidence of FSH, LH and PRL
binding was, respectively, 32%, 41% and 39% in normal ovaries, 30%, 18.5% and 22.5% in benign epithelial
tumours and 51%, 32% and 43% in malignant epithelial neoplasms.
The incidence of FSH binding was significantly higher in malignant epithelial neoplasms than in either
normal ovaries or benign epithelial tumours but otherwise no correlation was found between hormone
binding capacity and the degree of malignancy of epithelial ovarian tumours, the histological type of the
tumour, the degree of differentiation of the malignant epithelial tumours or the presence or absence of
metastatic disease. Well differentiated malignant tumours did, however, tend to stain more strongly than did
poorly differentiated neoplasms, thus suggesting that the number of binding sites per cell tends to decrease
with decreasing degrees ofdifferentiation.
The ovaries are under the trophic control of the
pituitary gonadotrophins, follicle-stimulating
hormone (FSH) and luteinising hormone (LH): a
third pituitary hormone, prolactin, almost certainly
has a role, though currently an ill defined one, in
the control of ovarian function. The part played by
these hormones, particularly the gonadotrophins, in
ovarian tumour genesis is currently a matter of
considerable interest, largely because of the
possibility that hypergonadotrophism may be an
aetiological factor in ovarian neoplasia (Beamer,
1981).
Biochemical studies have demonstrated specific
receptors for gonadotrophins and prolactin in
the normal human ovary (Poindexter et al., 1979;
McNeilly et al., 1980; Kammerman, 1980,
1981; Rao et al., 1981) and in ovarian neoplasms
(Davy et al., 1977; Kammerman et al., 1980, 1981;
Rajaniemi et al., 1981a) whilst immunoperoxidase
techniques have been used to demonstrate
gonadotrophin-binding sites in rat gonads (Petrusz
& Uhlarik, 1973; Petrusz, 1974; Childs et al., 1978;
Rajaniemi et al., 1981b) and prolactin-binding sites
in human prostate gland (Witorsch, 1978) and in
normal and neoplastic human breast tissue
(Paterson et al., 1982; Purnell et al., 1982; Dhadley
& Walker, 1983).
There have not, to the best of our knowledge,
been any reported immunohistochemical studies of
gonadotrophin and prolactin binding sites in
normal human ovaries or in ovarian neoplasms: the
aims of this study were (a) to repair this deficiency,
(b) to determine if the pattern of gonadotrophin
and prolactin binding in ovarian epithelial
neoplasms differs in benign, borderline and
malignant tumours and (c) to determine if there is
any relationship between the presence of
gonadotrophin and prolactin binding sites and the
histological type of ovarian neoplasm, the degree of
differentiation of malignant tumours and the
presence or absence of metastases.
Materials and methods
Material
Tissue from 99 normal ovaries and from 141
ovarian neoplasms was studied (Table I), all tissues
being obtained either from surgical specimens or
from biopsy material received in the Department of
Pathology, St. Mary's Hospital, Manchester. In 100
of the cases the material was received fresh: one
portion was snap frozen in liquid nitrogen whilst
the remainder was fixed in formalin. From the
other 140 cases only formalin-fixed tissue was
available.
Pituitary tissue was used as a positive tissue
control, and lung, myocardium and skeletal muscle,
serving as negative tissue controls, were obtained
from autopsy material.
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Table I
Tissues examinedfor thepresence ofFSH, LH and PRL
binding sites
Normal ovaries
Benign serous tumours
Serous tumours of borderline malignancy
Serous adenocarcinomas
Benign mucinous tumours
Mucinous tumours of borderline malignancy
Mucinous adenocarcinomas
Endometrioid tumours ofborderline malignancy
Endometrioid adenocarcinomas
Mesonephroid tumours of borderline malignancy
Mesonephroid adenocarcinomas
Brenner tumours
Mixed epithelial tumours
Undifferentiated adenocarcinomas
Granulosa cell tumours
Androblastomas
Theca cell tumours
Fibromas
Mature teratomas
Metastatic tumours
Total
99
14
11
20
17
5
12
1
11
1
4
7
4
4
5
2
9
3
6
5
240
Reagents
Rabbit antisera to the beta-subunits of LH and
FSH and to PRL, FSH and LH were partly
donated by NIAMDD and were also purchased
from Calbiochem-Behring Corp. FSH, LH and
PRL were purchased from Calbiochem-Behring
Corp.
Swine anti-rabbit immunoglobulin antiserum,
normal rabbit serum, normal swine serum and
rabbit peroxidase-l-antiperoxidase (PAP) were
obtained from Dako Immunoglobulins Ltd. whilst
diaminobenzidine tetrahydrochloride was purchased
from Aldrich Chemical Co.
Methods
Serial 5pm frozen and paraffin-embedded sections
were prepared by routine laboratory procedures
and assayed immunocytochemically for detection of
hormone binding using the double PAP method as
previously reported (Al Timimi et al., 1985). In
brief, paraffin sections were deparaffinised in xylene
and hydrated through graded alcohols. Endogenous
peroxidase activity was blocked by immersing the
section in a solution of 1% wt/vol hydrogen
peroxide in methanol for 1 h: the sections were then
washed for 1 h in Tris buffered saline (TBS) at pH
7.6 and subsequently incubated with a 1: 5 dilution
of normal swine serum for 5min in order to reduce
non-specific background staining. The sections were
then incubated with the appropriate hormone
(FSH, LH or PRL), at concentrations of 10-
20pgml-1 in TBS (pH 7.5) with (vol/vol) 1%
absolute ethanol, overnight at 4°C in a moist
chamber. Following this the sections were washed
and fixed for 5min in 1% paraformaldehyde to
stabilise the hormones at their binding sites. In
some sections from each case the step of addition
of hormones was omitted to demonstrate
endogenous in vivo hormone binding. The sections
were then washed with TBS and incubated
sequentially with the following antisera for the
times indicated: (i) rabbit anti-FSH (1:300), rabbit
anti-LH (1:300) or rabbit anti-PRL (1:200) for 24h
at 4°C: (ii) swine anti-rabbit immunoglobulin (SAR,
diluted 1:50, for 15min: (iii) PAP soluble complex
(1:100) for 30min: (iv) SAR (1:100) for 15min: (v)
PAP (1:100) for 15min. Unless noted otherwise all
incubations were conducted in a moist chamber at
room temperature. The sections were washed with
TBS (pH 7.6) after exposure to the primary
antisera, SAR and PAP.
The bound hormones were visualised by
incubating the slides for 5min with a filtered freshly
prepared solution of 50mg DAB in 100ml of TBS
(pH 7.6) to which was added 0.02ml of 30 vol
hydrogen peroxide per 100ml of substrate solution.
The slides were then counterstained with
haematoxylin, dehydrated to xylene and cover-
slipped with permount.
Specificity controls
Tissue controls Normal pituitary glands were used
as positive controls for FSH, LH and PRL staining
whilst sections from lung, myocardium and skeletal
muscle were used as negative tissue controls.
Method controls In every staining run one
component of the sequential staining reaction was
omitted from at least one section. Usually the
primary antiserum was replaced by normal rabbit
serum but sometimes SAR or PAP was replaced by
diluent buffer or DAB by TBS.
Absorption controls These were prepared by
mixing a purified hormone preparation with the
antiserum to this hormone for 24h at 4°C prior to
the inclusion of the antiserum in the IP procedure.
Quantitation ofresults
The degree of binding was scored on the basis of
the proportion of positively staining cases from +
to + + +, an admittedly arbitrary and subjective
grading system but nevertheless one which, in
practice, gave reproducible results.GONADOTROPHIN BINDING IN OVARIAN TISSUES 323
Statistical analysis
All the results obtained were subjected to a chi-
square test, a probability level of P<0.05, being
taken to represent statistical significance.
Results
A positive reaction for hormone binding was seen
as a brown granular precipitate after addition of
DAB. All the sections of presumably positive
pituitary tissue controls for LH, FSH and PRL
gave the expected positive result (Figure la) whilst
a negative reaction for hormone binding was
observed in non-target tissues. The omission of any
one component from the sequential immuno-
peroxidase stain resulted in totally negative results
as did the use of antisera which had been
previously absorbed by their corresponding
hormones (Figure lb). The results obtained in
(a)
Figure 1 (a) A section of normal human pituitary
gland showing FSH-dependent staining in the
gonadotrope cells (IPx 500). (b) Immunostaining of
human pituitary gland cells abolished by testing with
anti-FSH serum which had been previously absorbed
with hFSH (IP x 500).
formalin fixed and paraffin embedded tissues were
identical to those seen in frozen sections, both in
respect of the number of positively staining cells
and the strength of the staining reaction.
Endogenous in vivo binding of gonadotrophins
and prolactin was seen in many sections of both
normal and neoplastic ovarian tissue but the
staining was generally weak and occurred in the
same sites that subsequently showed binding of
exogenous gonadotrophins and prolactin under in
vitro conditions (Figure 2).
The incidences of a positive reaction for binding
of FSH, LH and PRL in both normal and
neoplastic ovarian tissue are shown in Table II. The
relationship between the presence of these binding
sites and the menopausal status of the patient, the
histological type of tumour, the histological grade
of the neoplasm and the presence or absence of
metastases are detailed in Tables II-V.
In the normal ovaries FSH binding was seen in
the granulosa cells of the pre-antral and antral
(a)
(b)
Figure 2 (a) A primary follicle in a normal human
ovary. A FSH-binding reaction is present in the ovum
and in the granulosa cells (IPx 500). (b) The same
follicle as shown in Figure 2a. Omission of initial FSH
incubation markedly diminishes the staining reaction
(IP x 500).324 A. AL-TIMIMI et al.
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Table III Relationship between presence of positive FSH, LH and PRL binding sites and histological
type of tumour
FSH-Positive LH-Positive PRL-Positive
Number
Tumour type ofcases No. (%) No. (%) No. (%)
Common epithelial tumours:
Serous 45 19 42 11 24.5 14 31
Mucinous 34 12 35 10 29.5 14 41
Endometrioid 12 5 41.5 3 25 3 25
Mesonephroid 5 4 80 2 40 3 60
Brenner 7 2 28.5 1 14 1 14
Mixed epithelial 4 2 50 1 25 1 25
Undifferentiated 4 2 50 1 25 2 50
Sex cordstromal tumours:
Granulosa cell 5 2 40 2 40 2 40
Androblastomas 2 2 100 2 100 1 50
Thecomas 9 3 33 4 44.5 3 33
Fibromas 3 0 0 0 0 0 0
Table IV Relationship between histological grade of malignant epithelial tumours and presence of
positive FSH, LH and PRL binding sites
FSH-Positive LH-Positive PRL-Positive
Histological Number
grading ofcases No. (%) No. (%) No. (%)
Well
differentiated 21 11 52 8 38 11 52
Moderately
differentiated 17 7 41 4 23.5 7 41
Poorly
differentiated 15 9 60 5 33 5 33
Table V Relationship between presence of positive FSH, LH and PRL binding sites and metastatic
status
FSH-Positive LH-Positive PRL-Positive
Metastatic Number
status ofcases No. (%) No. (%) No. (%)
Metastases
present 30 15 50 10 33 13 43
Metastases
absent 23 12 52 7 30 10 43
follicles (Figure 2a) but was minimal or absent in
atretic follicles. The binding sites in the reactive
granulosa cells appeared to be localised in the
cytoplasm or, in a minority of cases, in the nucleus.
Binding of FSH to stromal cells was also seen. LH
binding was seen in the granulosa cells of large
antral follicles and in the stromal cells. Within the
granulosa cells the pattern of binding was similar to
that of FSH binding though LH binding appeared
to be purely cytoplasmic in the stromal cells. LH
binding was also seen in both granulosa cells and
thecal cells of corpora lutea. PRL binding followed326 A. AL-TIMIMI et al.
'."f. . K
(a)
Figure 3 A corpus luteum in a normal human ovary.
The lutein cells show a uniformly positive staining for
PRL-binding (IP x 370).
the general pattern of LH binding but a notably
strong reaction was observed in the luteinised cells
ofcorpora lutea (Figure 3).
Of the 111 epithelial ovarian tumours studied, 46
(41.4%) stained positively for FSH binding, 29
(26%) for LH binding and 38 (34%) for PRL
binding. As compared with normal ovarian tissue
or with benign epithelial tumours there was a
statistically significant excess of FSH binding in
malignant epithelial tumours whilst the incidence of
PRL binding was significantly greater in malignant
epithelial ovarian tumours than in benign epithelial
neoplasms of the ovary. There was no significant
correlation between the presence of hormone
binding sites and the menopausal status of the
patient, the histological type of epithelial ovarian
tumour, the degree of malignancy of ovarian
epithelial tumours or with the presence or absence
of metastatic disease.
Hormone binding sites were not demonstrated in
mature ovarian teratomas or in metastatic tumours
of the ovary but in sex cord stromal tumours, FSH
binding was demonstrable in 37% of cases, LH
binding in 42% and PRL binding in 31.5%.
Within ovarian neoplasms DAB granules were
seen principally in the cytoplasm of the neoplastic
epithelial cells (Figures 4 and 5) but in some cases
staining was restricted to focal areas of the tumour
cell membrane whilst in others staining was
predominantly nuclear. A striking feature of the
pattern with ovarian neoplasms was the marked
heterogeneity of the tumour cells for binding sites
to all the studied hormones, strongly staining cells
being admixed with cells which gave totally
negative staining reactions (Figure 6).
(b)
Figure 4 (a) An endometrioid adenocarcinoma of the
ovary showing a positive staining reaction for FSH-
binding in epithelial and periepithelial stromal cells
(IP x 500). (b) A section of the same tumour as shown
in Figure 4a: initial FSH incubation was omitted in
order to show in vivo binding of endogenous FSH
(IP x 500).
Discussion
In this study FSH, LH and PRL binding sites have
been demonstrated by immunohistochemical
techniques in a considerable proportion of normal
human ovaries and in many ovarian epithelial
tumours. Our finding that formalin-fixed, paraffin
embedded tissue sections can be used to detect both
in vivo and in vitro binding sites is in accord with
the results of other immunohistochemical studies of
gonadotrophin binding sites in rat testes (Childs et
al., 1978; Rajaniemi et al., 1981b) and rat ovaries
(Petrusz & Uhlahrik, 1973; Petrusz, 1974; Petrusz &
Sar, 1978) and with studies of PRL binding sites in
rat ovaries (Nolin, 1978, 1980; Dunaif et al., 1977,
1982) in human, dog and rat prostatic tissue
(Eletreby & Mahrous, 1979; Witorsch, 1978, 1979a,
1979b; Purnell et al., 1982), dog breast tissueGONADOTROPHIN BINDING IN OVARIAN TISSUES 327
(a)
......~'
(b)
Figure 5 (a) A serous tumour of borderline
malignancy stained for PRL-binding (IP x 500). (b)
The same tumour as shown in Figure 5a: initial PRL
incubation was omitted in order to show in vivo
binding ofendogenous PRL (IP x 500).
(a)
Figure 6 A Brenner tumour stained for FSH-binding.
There is a markedly heterogenous pattern of tumour
cell staining (IP x 630).
(Eletreby & Mahrous, 1979) and mouse adrenal
gland (McDonough & Ewig, 1982). Dhadley and
Walker (1983) were, however, unable to detect PRL
binding in paraffin-embedded sections of human
breast tissue and advocated the sole usage of frozen
sections: it appears therefore that the stability of
binding sites for PRL varies from organ to organ.
The validity of immunoperoxidase techniques for
the demonstration of hormone receptor sites has
been subjected to stringent criticism (Zehr et al.,
1981; McCarty et al., 1981; Underwood, 1983) but
we have elsewhere countered these arguments (Al-
Timimi et al., 1985) and have pointed out that
immunohistochemical techniques appear to
demonstrate hormone binding to specific
recognition sites. It could, of course, be argued that
the technique used here simply demonstrates sites
of non-specific absorption but this would leave
open the question as to why such non-specific
binding is not seen in non-target tissues. The
specific recognition sites shown by immunohisto-
chemical techniques probably do not coincide in
their entirety with the receptors measured by
biochemical cytosol assays but nevertheless given an
equally characteristic picture of the hormone-
binding capacity ofparticular cells and tissues. This
is emphasised by a comparison of our findings with
those reported by workers using biochemical
techniques to demonstrate FSH, LH and PRL
receptors for our results are very similar to those
obtained by Kammerman (1980), Kammerman et
al. (1981) and Rajaniemi et al. (1981). Our results
in respect to PRL binding in normal human
ovarian tissue are also in accord with previous
biochemical studies (Poindexter et al., 1979;
McNeilly et al., 1980): there have been no previous
reports of the frequency of PRL binding in ovarian
enithelial tumours but our results for neoDIasms of
this type correspond very closely to reports of the
incidence of biochemically assayable PRL receptors
in human breast carcinomas (Di Carlo et al., 1980;
Turcot-Lemay & Kelly, 1982).
In this study those ovarian epithelial neoplasms
showing a positive reaction for FSH, LH or PRL
binding showed a striking degree of heterogeneity
with strongly staining cells admixed with totally
negative cells. This was not unexpected but in
addition, however, ovarian adrenocarcinomas were
heterogenous in respect to the cellular localisation
of bound gonadotrophins and prolactin. A similar
heterogeneity of cellular staining pattern has
previously been noted in rat prostatic carcinomas
(Witorsch, 1979a,b), in human prostatic carcinoma
(Purnell et al., 1982) and in human breast
carcinomas (Paterson et al., 1982; Purnell et al.,
1982; Dhadley & Walker, 1983). This variable
pattern of staining for gonadotrophin and prolactin328 A. AL-TIMIMI et al.
binding sites suggests that there may be sub-
populations of ovarian carcinoma cells with
differing hormone binding abilities or under
different hormonal controls. Until recently the
dogma has been that the binding sites for
gonadotrophins, like those for other protein
hormones, are exclusively present in the limiting
membranes of target tissue cells. Recent studies
have, however, contradicted this traditional belief
by showing that not only the plasma membranes
but also various intracellular organelles contain
gonadotrophin receptors (Rao et al., 1981;
Rajandran & Menon, 1983). Immunoperoxidase
studies have also shown that intracellular prolactin
is present in rat ovaries (Dunaif et al., 1977, 1982;
Nolin, 1978, 1980) and in human breast and
prostatic tissue (Purnell et al., 1982) whilst
intracellular gonadotrophins have been
demonstrated in rat ovary (Petrusz & Uhlarik,
1973; Petrusz, 1974; Petrusz & Sar, 1978) and
human prostate (Sibley, 1981).
Our findings in respect to the clinical or
prognostic value of the demonstration of gonado-
trophin and prolactin binding sites were dis-
appointing. It would have been expected that well
differentiated epithelial tumours were more likely to
have demonstrable hormone binding sites than
would poorly differentiated neoplasms but this
proved not to be the case. It is worth noting,
however, that the strength of the reaction obtained
did vary considerably with the degree of tumour
differentiation. Thus, the staining reaction for FSH
binding was strong (+ + +) in 54% of well
differentiated tumours showing binding for this
hormone but attained this degree of staining
intensity in only 22% of positively reacting
neoplasms which were poorly differentiated. The
equivalent figures for LH binding were 37.5 and
0% whilst those for prolactin binding were 36 and
0%. These figures suggest that whilst the number of
cells with hormone binding sites does not alter with
decreasing differentiation of an ovarian tumour the
number of binding sites in each individual cell does,
there being a progressive decrease in staining
intensity with decreasing degrees of cellular
differentiation.
The incidence of FSH binding was significantly
higher in malignant epithelial neoplasms than in
either normal ovaries or benign epithelial
neoplasms. This observation can, of course, be
interpreted in several ways but would certainly tend
to support the view that FSH plays a role in
ovarian tumourigenesis. It has traditionally been
thought, however, that if FSH does indeed play a
role in this respect it does so by increasing the
number of inclusion cysts derived from the ovarian
surface epithelium rather than by promoting
malignant change in such cysts. The observation
that an increased incidence of FSH-binding was
noted in malignant but not in benign epithelial
neoplasms of the ovary would tend to argue against
this concept.
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